These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39090179)

  • 1. Factors influencing the efficacy and safety of esaxerenone in hypertensive patients: a pooled analysis of five clinical studies on different comorbidities.
    Kario K; Katsuya T; Wada J; Motoki H; Kuwahara K; Tsujita K; Taguchi T; Tanabe A; Shimosawa T
    Hypertens Res; 2024 Oct; 47(10):2826-2839. PubMed ID: 39090179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
    Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
    Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
    Kario K; Nishizawa M; Kato M; Ishii H; Uchiyama K; Nagai M; Takahashi N; Asakura T; Shiraiwa T; Yoshida T; Kaneshiro M; Taguchi T; Shiosakai K; Sugimoto K
    Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker.
    Kario K; Ohbayashi H; Hashimoto M; Itabashi N; Kato M; Uchiyama K; Hirano K; Nakamura N; Miyamoto T; Nagashima H; Ishida H; Ebe Y; Hatta T; Fukui T; Shimosawa T; Katsuya T; Taguchi T; Tanabe A; Ohishi M;
    Hypertens Res; 2024 Oct; ():. PubMed ID: 39394512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study.
    Kario K; Ohbayashi H; Hashimoto M; Itabashi N; Kato M; Uchiyama K; Hirano K; Nakamura N; Miyamoto T; Nagashima H; Kajiyama S; Ishida H; Imai E; Ebe Y; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Shimosawa T;
    Hypertens Res; 2024 Sep; 47(9):2435-2446. PubMed ID: 39039285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
    Ito S; Okuda Y; Sugimoto K
    Adv Ther; 2023 Mar; 40(3):1242-1266. PubMed ID: 36662393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
    Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
    Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
    Yamamoto E; Usuku H; Sueta D; Suzuki S; Nakamura T; Matsui K; Matsushita K; Iwasaki T; Sakaino N; Sakanashi T; Hirayama K; Kurokawa H; Kikuta K; Yamamoto N; Sato K; Tokitsu T; Taguchi T; Shiosakai K; Sugimoto K; Tsujita K;
    Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
    Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
    Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
    Motoki H; Inobe Y; Fukui T; Iwasaki A; Hiramitsu S; Koyama S; Masuda I; Sekimura N; Yamamoto K; Sato A; Komatsu M; Taguchi T; Shiosakai K; Sugimoto K; Kuwahara K
    Adv Ther; 2023 Nov; 40(11):5055-5075. PubMed ID: 37733211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
    Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
    Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home.
    Hashimoto J; Hirayama H; Hanasawa T; Watabe D; Asayama K; Metoki H; Kikuya M; Ohkubo T; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 May; 27(4):331-41. PubMed ID: 15921070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
    Mori Y; Nishikawa Y; Iizuka T; Zenimura N; Matsumoto T; Hiramatsu K; Komiya M
    Drugs R D; 2011; 11(2):171-90. PubMed ID: 21679007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
    Malacco E; Omboni S; Mallion JM; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of azelnidipine tablets on morning hypertension.
    Kario K; Sato Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
    Drugs R D; 2013 Mar; 13(1):63-73. PubMed ID: 23512719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.